Gene analysis in BRCA carriers with and without early tubal changes
Part of Cancer, Genetic & congenital clinical trials.
This study looks at the genetic activity in ovarian and fallopian tube tissue from women with and without BRCA mutations. It aims to find early changes that might lead to cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You need to have a known BRCA1 or BRCA2 gene change (mutation) or be confirmed not to have one, depending on the group.
- You must have had healthy ovarian tissue (with no cancer) removed and stored in a wax block (FFPE).
- For some groups, you must also have had a tiny very early precancer called STIC in the fallopian tube.
- You cannot have had ovarian, fallopian tube, or peritoneal cancer before, or have received chemotherapy or radiation to the pelvis before the tissue was taken.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows women who carry BRCA1 or BRCA2 gene variants (or a gene variant of unclear meaning) to learn about their risks over time. It may help improve how genetic information is used to guide future care.
This study looks for early signs of ovarian cancer in a simple blood test. It may help people with BRCA gene changes catch problems sooner, before or after preventive surgery.
This study collects blood (and possibly tumor tissue) to learn how certain inherited gene changes relate to breast and ovarian cancer risk. It may help researchers understand which people are most likely to develop these cancers and how tumors differ in high-risk patients.
This study follows people who carry a harmful BRCA1 or BRCA2 gene mutation, whether or not they currently have breast or ovarian cancer. The goal is to better understand cancer risk over time and how being a carrier may affect screening and care.
This is an observational study that looks at how different cancer prevention approaches affect women with harmful (deleterious) BRCA1 or BRCA2 mutations. It may help improve future prevention and follow-up plans for women at higher inherited risk.
This study looks at fertility in women who carry a BRCA1 or BRCA2 gene mutation. It aims to understand how these mutations might affect a woman's ability to have children by comparing them to family members without the mutation.
Hear when a new Transcriptomics trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.